Off-label prescribing in pediatric outpatients

Pediatrics

Volumn 135, Issue 1, 2015, Pages 49-58

  Palmaro, Aurore ^a   Bissuel, Raphael ^a   Renaud, Nicholas ^a   Durrieu, Geneviève ^a   Escourrou, Brigitte ^a   Oustric, Stephane ^a   Montastruc, Jean Louis ^a   Lapeyre Mestre, Maryse ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BETAMETHASONE; CEFPODOXIME; CORTICOSTEROID; DECONGESTIVE AGENT; DESLORATADINE; GASTROINTESTINAL AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IBUPROFEN; MEASLES MUMPS RUBELLA VACCINE; MEQUITAZINE; ORAL REHYDRATION SOLUTION; PARACETAMOL; PHLOROGLUCINOL; PREDNISOLONE; RIFAMYCIN; TIXOCORTOL; TUAMINOHEPTANE; VACCINE;

ADOLESCENT; ADVERSE DRUG REACTION; ARTICLE; BRONCHITIS; CHILD; COUGHING; DRUG CONTRAINDICATION; DRUG RECALL; DRUG UNDERDOSE; ERYTHEMA; FEMALE; FRANCE; GENERAL PRACTITIONER; HUMAN; INAPPROPRIATE PRESCRIBING; INFANT; LARYNGITIS; LUNG DISEASE; MALE; MEDICATION ERROR; NEWBORN; OFF LABEL DRUG USE; OUTPATIENT; PRURITUS; RHINITIS; UNLICENSED DRUG USE; UNSPECIFIED SIDE EFFECT; CLINICAL PRACTICE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENERAL PRACTICE; PRESCHOOL CHILD; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENERAL PRACTICE; HUMANS; INFANT; MALE; OFF-LABEL USE; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES;

EID: 84920427603     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0764     Document Type: Article

References (32)

1. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5(5):703-718
2. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54(6):665-670
3. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999; 88(9):965-968
4. Star K, Edwards IR. Pharmacovigilance for children's sake. Drug Saf. 2014;37(2): 91-98
5. Lalande J. [Appel, a general pediatrics child welfare organization]. Arch Pediatr. 2003;10(suppl 1):245s-247s
6. Lehmann B. Regulation (EC) No 1901/ 2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health. 2008;2(1):37
7. Frattarelli DA, Galinkin JL, Green TP, et al; American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014; 133(3):563-567
8. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009;94(9):724-728
9. Sorum PC. Two tiers of physicians in France: general pediatrics declines, general practice rises. JAMA. 1998; 280(12):1099-1101
10. Bocquet A, Chalumeau M, Bollotte D, Escano G, Langue J, Virey B. Comparison of prescriptions by pediatricians and general practitioners: a populationbased study in Franche-Comte from the database of Regional Health Insurance Fund. Arch Pediatr. 2005;12(12): 1688-1696
11. International Conference on Harmonisation (ICH). ICH harmonised tripartite guideline E11: clinical investigation of medicinal products in the pediatric population. 2000. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E11/Step4/E11-Guideline.pdf
12. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine. 2011;29(19): 3610-3616
13. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French National Health Insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010; 58(4):286-290
14. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Répertoire des spécialités pharmaceutiques. Available at: http://agence-prd.ansm.sante.fr/php/ecodex/index.php. Accessed March 12, 2014
15. Bégaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985; 40(2):111-118
16. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237): 1255-1259
17. Bonnes pratiques de pharmacovigilance. Mise à jour prenant en compte l'arrêté du 10 juin 2011 relatif aux modalités de signalement des effets indésirables par les patients et les associations agréées de patients. Available at: http://ansm.sante.fr/var/ansm-site/storage/original/application/13df5d1566a748c2f08299233451fe5c.pdf. Accessed March 12, 2014
18. Chalumeau M, Tréluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child. 2000; 83(6):502-505
19. Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a populationbased study in Germany. BMC Public Health. 2013;13(1):631
20. Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9(2):81-88
21. Lass J, Irs A, Pisarev H, Leinemann T, Lutsar I. Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf. 2011; 20(5):474-481
22. Olsson J, Kimland E, Pettersson S, Odlind V. Paediatric drug use with focus on offlabel prescriptions in Swedish outpatient care - a nationwide study. Acta Paediatr. 2011;100(9):1272-1275
23. Carnovale C, Conti V, Perrone V, et al. Paediatric drug use with focus on offlabel prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172(12): 1679-1685
24. Smyth RM, Gargon E, Kirkham J, et al. Adverse drug reactions in children - a systematic review. PLoS ONE. 2012;7(3): e24061
25. Aagaard L, Hansen EH. Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactions. Br J Clin Pharmacol. 2011; 71(5):751-757
26. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol. 2014;77(3):545-553
27. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004; 27(13):1059-1067
28. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol. 2012;68(1):21-28
29. Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111(2):291-295
30. Haslund-Krog S, Mathiasen R, Christensen HR, Holst H. The impact of legislation on drug substances used off-label in paediatric wards - a nationwide study. Eur J Clin Pharmacol. 2014;70(4):445-452
31. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A. Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol. 2011;67(3): 245-252
32. Milne CP, Davis J. The pediatric studies initiative: after 15 years have we reached the limits of the law? Clin Ther. 2014; 36(2):156-162